BRPI0410423A - processo de imunogenicidade melhorada para vacinação meningocócica - Google Patents

processo de imunogenicidade melhorada para vacinação meningocócica

Info

Publication number
BRPI0410423A
BRPI0410423A BRPI0410423-4A BRPI0410423A BRPI0410423A BR PI0410423 A BRPI0410423 A BR PI0410423A BR PI0410423 A BRPI0410423 A BR PI0410423A BR PI0410423 A BRPI0410423 A BR PI0410423A
Authority
BR
Brazil
Prior art keywords
improved immunogenicity
immunogenicity
vaccination
meningococcal vaccination
improved
Prior art date
Application number
BRPI0410423-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Robert P Ryall
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of BRPI0410423A publication Critical patent/BRPI0410423A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0410423-4A 2003-05-07 2004-05-07 processo de imunogenicidade melhorada para vacinação meningocócica BRPI0410423A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46858303P 2003-05-07 2003-05-07
PCT/US2004/014337 WO2005004909A2 (en) 2003-05-07 2004-05-07 Method of enhanced immunogenicity to meningococcal vaccination

Publications (1)

Publication Number Publication Date
BRPI0410423A true BRPI0410423A (pt) 2006-06-06

Family

ID=34061894

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410423-4A BRPI0410423A (pt) 2003-05-07 2004-05-07 processo de imunogenicidade melhorada para vacinação meningocócica

Country Status (8)

Country Link
US (1) US20050002948A1 (enExample)
EP (2) EP2301571A1 (enExample)
JP (2) JP2007516219A (enExample)
CN (1) CN1819843A (enExample)
AU (2) AU2004255526A1 (enExample)
BR (1) BRPI0410423A (enExample)
CA (1) CA2524853A1 (enExample)
WO (1) WO2005004909A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1154790E (pt) * 1999-02-26 2005-03-31 Chiron Srl Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
GB0406013D0 (en) * 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0500787D0 (en) * 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
PL1740217T3 (pl) * 2004-04-30 2012-03-30 Novartis Ag Szczepienie koniugatem meningokokowym
US20060088554A1 (en) * 2004-08-30 2006-04-27 Ryall Robert P Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
WO2007026249A2 (en) 2005-09-01 2007-03-08 Novartis Vaccines And Diagnostics Gmbh & Co Kg Multiple vaccination including serogroup c meningococcus
WO2007102797A2 (en) * 2005-12-22 2007-09-13 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
AU2006327023A1 (en) * 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines
KR101411425B1 (ko) 2006-03-17 2014-06-24 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
EP2007427A4 (en) 2006-04-11 2012-04-04 Yeda Res & Dev IMPROVED VACCINES WITH MULTIMETER HSP60 PEPTIDE SUPPORTS
US7491517B2 (en) 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
US8394391B2 (en) * 2007-08-31 2013-03-12 University Of Utah Research Foundation Drug delivery vehicle that mimics viral properties
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
US8003112B2 (en) * 2009-04-16 2011-08-23 Howard University Meningococcal and pneumococcal conjugate vaccine and method of using same
CA2761733C (en) * 2009-06-01 2019-01-08 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Reagents and methods for detecting influenza virus proteins
WO2011112906A2 (en) * 2010-03-12 2011-09-15 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
CN103025351B (zh) * 2010-05-28 2016-08-24 佐蒂斯比利时股份有限公司 包含胆固醇和作为唯一的佐剂-载剂分子的cpg的疫苗
CN102462839B (zh) * 2010-11-12 2016-03-30 北京生物制品研究所 多糖结合疫苗及其制备方法
JP6366501B2 (ja) 2011-05-11 2018-08-01 ザ チルドレンズ メディカル センター コーポレーション 修飾ビオチン結合タンパク質、その融合タンパク質、および用途
US10428955B2 (en) * 2012-06-25 2019-10-01 Hamilton Sundstrand Corporation Contamination resistant butterfly valve
CN103100081A (zh) * 2012-12-26 2013-05-15 天津康希诺生物技术有限公司 一种多价联合疫苗
ES2959258T3 (es) 2013-02-07 2024-02-22 Childrens Medical Center Antígenos proteicos que proporcionan protección contra la colonización y/o la enfermedad neumocócicas
CN107674118A (zh) * 2016-08-02 2018-02-09 中国食品药品检定研究院 重组蛋白PspA1、PspA2和PspA3以及包含其的多糖结合疫苗
CN106167519A (zh) * 2016-08-10 2016-11-30 成都生物制品研究所有限责任公司 一种破伤风类毒素的制备方法
WO2018183475A1 (en) 2017-03-28 2018-10-04 Children's Medical Center Corporation A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
ES2967001T3 (es) 2017-06-23 2024-04-25 Affinivax Inc Composiciones inmunogénicas
JP7535791B2 (ja) 2018-09-12 2024-08-19 ザ チルドレンズ メディカル センター コーポレーション 肺炎球菌融合タンパク質ワクチン
WO2020056202A1 (en) 2018-09-12 2020-03-19 Affinivax, Inc. Multivalent pneumococcal vaccines
CN109402035A (zh) * 2018-11-06 2019-03-01 华中农业大学 一种肠外致病性大肠杆菌重组菌株及其应用
KR102871663B1 (ko) * 2019-09-27 2025-10-16 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법
CN111024946A (zh) * 2019-11-19 2020-04-17 江苏美克医学技术有限公司 阴道毛滴虫荧光免疫层析测定试剂盒及其制备方法
KR20240099160A (ko) 2021-09-09 2024-06-28 아피니백스, 인크. 다가 폐렴구균 백신

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5422427A (en) 1991-09-17 1995-06-06 The United States Of America As Represented By The United States Department Of Health And Human Services Pneumococcal fimbrial protein A
US5445817A (en) 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
SI1296715T2 (sl) 2000-06-29 2016-03-31 Smithkline Beecham Biologicals S.A. Multivalentni sestavek cepiva
EP2957300B1 (en) * 2001-01-23 2021-07-14 Sanofi Pasteur Inc. Multivalent meningococcal polysaccharide-protein conjugate vaccine

Also Published As

Publication number Publication date
JP2007516219A (ja) 2007-06-21
AU2004255526A1 (en) 2005-01-20
WO2005004909A3 (en) 2005-06-02
CN1819843A (zh) 2006-08-16
EP1626737A2 (en) 2006-02-22
WO2005004909A2 (en) 2005-01-20
EP2301571A1 (en) 2011-03-30
AU2010257354A1 (en) 2011-01-20
CA2524853A1 (en) 2005-01-20
JP2011068676A (ja) 2011-04-07
US20050002948A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
BRPI0410423A (pt) processo de imunogenicidade melhorada para vacinação meningocócica
FR11C0001I2 (fr) Vaccins combines contre neisseria meningitidis
PL1670506T3 (pl) Płynne szczepionki przeciw wielu grupom serologicznym meningokoków
CR10123A (es) Vacuna.
RU2006140958A (ru) Иммунизация против менингококков серогруппы y с помощью белков
MA30065B1 (fr) Vaccin
NZ598367A (en) Multiple vaccination including serogroup C meningococcus
BR0308768A (pt) Sacarìdeos modificados possuindo estabilidade melhorada em água
EP2433647A3 (en) GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
BR0015958A (pt) Composições que compreendem antìgenos de neisseria meningitidis de sorogrupos b e c
MA29406B1 (fr) Vaccin toxoide alpha de c. perfringens
AP2004003074A0 (en) Adjuvanted antigenic meningococcal compositions
ATE552844T1 (de) Injizierbarer impfstoff gegen multiple meningokokken-serogruppen
WO2002009643A3 (en) Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
AU2002252638A1 (en) Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
AU2457100A (en) Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
BRPI0411815A (pt) vacinas contra neisseria meningitidis do tipo y e suas combinações meningocócicas
WO2010027499A3 (en) Methods, compositions and vaccines relating to neisseria meningitidis antibodies

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.